
A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on December 3-4, 2023 with the following interim recommendations made:
• Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen, remain in Schedule III and
• Acetaminophen and ibuprofen in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen, remain in Schedule II
• Brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older be granted Unscheduled status
• Brimonidine or its salts, except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older, will remain in Schedule I (as per the Prescription Drug List)
Any objections to these interim recommendations must be received by the NAPRA office by end of day January 11, 2024. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.
Subscribe to Updates from NAPRA
Receive NAPRA updates of interest directly to your inbox: general NAPRA news, NDS updates and/or updates on practice resources.